Amphiphysin Antibody IgG, CSF
Also known as: AMPHI CSF
Use
The Amphiphysin Antibody IgG, CSF test is primarily used in individuals with conditions such as stiff-person syndrome, paraneoplastic encephalomyelitis (PEM), and sensory neuronopathy (SN). It aids in the diagnosis of occult tumors, recurrence of tumors, or the presence of a second tumor. Amphiphysin antibodies are present in about 5 percent of patients with stiff-person syndrome and can be found variably in other paraneoplastic neurological syndromes (PNS). The antibody is closely associated with small-cell lung cancer and breast tumors.
Special Instructions
Amphiphysin antibodies in CSF may provide additional diagnostic information, especially when serum results are inconclusive or when testing for central nervous system involvement in paraneoplastic syndromes. Serum specimens are preferred, and see Amphiphysin Antibody, IgG (2008893) for serum testing.
Limitations
This test has not been cleared or approved by the U.S. Food and Drug Administration. It is performed in a CLIA-certified laboratory and intended for clinical purposes. The presence of amphiphysin antibodies is not solely indicative of a specific disease, and results should be interpreted within the context of a comprehensive clinical evaluation.
New York Approved
Methodology
Immunoassay (Western Blot)
Biomarkers
LOINC Codes
- 57750-2
Result Turnaround Time
1-4 days
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
1 mL
Minimum Volume
0.60 mL
Container
ARUP Standard Transport Tube
Storage Instructions
Refrigerated.
Causes for Rejection
Contaminated, heat-inactivated, hemolyzed, or lipemic specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 2 weeks |
| Frozen | 1 month |